Veterinary Vaccine Market
Veterinary Vaccine Market Forecasts to 2032 - Global Analysis By Type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines and Other Types), Animal, Disease, Technology, End User and By Geography
|
Years Covered |
2024-2032 |
|
Estimated Year Value (2025) |
US $12.98 BN |
|
Projected Year Value (2032) |
US $21.97 BN |
|
CAGR (2025-2032) |
7.8% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
Asia Pacific |
|
Highest Growing Market |
North America |
According to Stratistics MRC, the Global Veterinary Vaccine Market is accounted for $12.98 billion in 2025 and is expected to reach $21.97 billion by 2032 growing at a CAGR of 7.8% during the forecast period. A veterinary vaccine is a biological preparation used to protect animals from specific infectious diseases by stimulating their immune systems. It contains antigens derived from pathogens such as viruses, bacteria, or parasites, which trigger an immune response without causing the disease itself. Veterinary vaccines are essential tools in preventing disease outbreaks, enhancing animal welfare, and improving food safety. They are widely used in both domestic pets and livestock to reduce the spread of zoonotic diseases, boost productivity, and decrease reliance on antibiotics in animal health management.
According to the National Bureau of Statistics China, China produced 57.94 million tonnes of pig meat in 2023, which represented a 5% increase from the previous year.
Market Dynamics:
Driver:
Rising prevalence of zoonotic diseases and livestock infections
The need for preventive measures to protect public health is growing as more diseases spread from animals to people. In order to protect animals and avoid financial losses due to disease outbreaks, livestock producers are spending money on vaccines. Vaccination programs are being promoted by governments and health organisations in an effort to curb the spread of illnesses. The need for updated and sophisticated vaccinations is further increased by the appearance of new disease strains. Innovation and growth in the veterinary vaccine sector are being driven by this increased urgency and awareness.
Restraint:
High cost and stringent regulatory approvals
Innovative vaccine development necessitates a large investment in cutting-edge technology and specialised knowledge. These costs frequently postpone product debuts and restrict access for smaller competitors. The intricacy is increased by strict regulatory approvals, which call for a great deal of safety and effectiveness testing. Time-to-market increases and innovation is discouraged by the drawn-out and expensive approval processes. All of these variables work together to limit the availability and growth of new veterinary vaccinations around the world.
Opportunity:
Advancements in vaccine technology and personalized animal care
Immune response is improved and adverse effects are decreased by innovations including vector-based vaccinations, mRNA-based vaccines, and recombinant DNA technologies. Faster reactions to newly developing zoonotic diseases are also made possible by these technologies. Demand for specialised vaccination plans based on species, breed, and health status is being driven by personalised animal care. Animal productivity and disease prevention are enhanced by this focused strategy. When taken as a whole, these dynamics greatly increase the market for veterinary vaccines' growth and relevance.
Threat:
Vaccine resistance and limited cold chain infrastructure in low-income regions
Cultural beliefs, misinformation, and doubts about the effectiveness of vaccines all play a part in this resistance. Furthermore, inadequate cold chain infrastructure compromises the effectiveness of vaccinations by affecting how they are stored and transported. The problem is made worse by inadequate refrigeration equipment and an unstable electrical supply. Disease outbreaks and vaccination coverage decline as a result of these issues. As a result, the veterinary vaccine market's expansion and efficacy in these areas continue to be limited.
Covid-19 Impact
The COVID-19 pandemic moderately impacted the Veterinary Vaccine Market. While disruptions in supply chains and reduced veterinary visits during lockdowns temporarily hindered vaccine distribution and sales, the sector rebounded as pet adoption increased and awareness of animal health grew. Governments and stakeholders emphasized disease prevention in animals to avoid zoonotic outbreaks, driving demand for vaccines. Moreover, advancements in biotechnology and diagnostic tools, inspired by the pandemic, accelerated innovation in veterinary vaccine development, supporting market recovery and long-term growth.
The recombinant vaccines segment is expected to be the largest during the forecast period
The recombinant vaccines segment is expected to account for the largest market share during the forecast period, due to safer immunization solutions. These vaccines reduce the risk of reversion to virulence, enhancing animal safety and vaccine stability. They enable rapid development against emerging diseases, supporting timely responses to outbreaks. Their efficiency in inducing strong immune responses leads to reduced dosage frequency and improved compliance. Additionally, the growing adoption of advanced biotechnology in veterinary medicine fuels the demand for recombinant vaccines globally.
The homecare settings segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by enabling convenient and timely administration of vaccines, especially for companion animals. It reduces the need for frequent veterinary clinic visits, making preventive care more accessible and less stressful for pets and owners. Growing pet ownership and increasing awareness about animal health are driving demand for home-use vaccines and related services. Technological advancements like easy-to-use vaccine delivery systems further support at-home administration. This shift enhances vaccination compliance and boosts overall market growth.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing livestock populations, rising awareness of animal health, and supportive government initiatives. Countries like China, India, and Australia are witnessing increased demand for vaccines against foot-and-mouth disease, swine fever, and avian influenza. Expanding meat and dairy industries, along with improving veterinary infrastructure, further boost the market. However, challenges like regulatory barriers and limited cold chain logistics persist in rural areas.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced animal healthcare systems, strong R&D investments, and a high focus on companion animal health. The U.S. and Canada lead in innovation and vaccine adoption, with widespread use of technologies like DNA and recombinant vaccines. Stringent regulatory frameworks ensure vaccine quality but also pose entry challenges for new products. Unlike Asia Pacific, pet insurance and veterinary service access significantly influence market dynamics, reflecting the region’s mature and technology-intensive approach.
Key players in the market
Some of the key players profiled in the Veterinary Vaccine Market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Ceva Santé Animale, Elanco Animal Health, Virbac S.A., HIPRA, Phibro Animal Health Corporation, Vaxxinova International B.V., Biogénesis Bagó, Hester Biosciences Limited, Indian Immunologicals Ltd., Neogen Corporation, Tianjin Ringpu Bio?Technology Co., Ltd., China Animal Husbandry Group, Jinyu Bio?technology Co., Ltd., Ourofino Saúde Animal and Vetoquinol.
Key Developments:
In June 2025, Boehringer Ingelheim entered a strategic collaboration with Eko Health, a leader in AI-powered detection of heart and lung diseases, to improve heart murmur detection in dogs. This partnership combines BI’s expertise in canine cardiology with Eko’s digital stethoscope and AI algorithms. The collaboration aims to launch a canine-specific heart murmur detection algorithm via an Eko mobile app in 2026, enhancing early diagnosis and care for canine heart disease.
In March 2025, Zoetis collaborated with the Federation of European Companion Animal Veterinary Associations (FECAVA) and the Federation of Veterinarians of Europe (FVE) to launch a handbook promoting best practices and policy recommendations to strengthen the human-animal bond. This initiative highlights Zoetis’s commitment to advancing animal and human health through multi-stakeholder engagement.
In September 2024, Boehringer Ingelheim acquired Saiba Animal Health, a Swiss company specializing in therapeutic vaccines for companion animals. The acquisition brings SAH’s virus-like particle vaccine platform into BI’s R&D portfolio, targeting chronic diseases such as allergies, inflammation, and pain in pets. This move builds on previous collaborations between the companies and is expected to accelerate the development of innovative therapeutic vaccines with longer-lasting effects.
Types Covered:
• Inactivated (Killed) Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• DNA Vaccines
• Subunit Vaccines
• Other Types
Animals Covered:
• Companion Animals
• Production Animals
Diseases Covered:
• Canine Distemper
• Rabies
• Avian Influenza
• Newcastle Disease
• Brucellosis
• Bovine Viral Diarrhea (BVD)
• Other Diseases
Technologies Covered:
• Conventional Vaccines
• Advanced Vaccines
End Users Covered:
• Veterinary Hospitals & Clinics
• Livestock Farms
• Homecare Settings
• Research Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Veterinary Vaccine Market, By Type
5.1 Introduction
5.2 Inactivated (Killed) Vaccines
5.3 Live Attenuated Vaccines
5.4 Toxoid Vaccines
5.5 Recombinant Vaccines
5.6 DNA Vaccines
5.7 Subunit Vaccines
5.8 Other Types
6 Global Veterinary Vaccine Market, By Animal
6.1 Introduction
6.2 Companion Animals
6.2.1 Dogs
6.2.2 Cats
6.3 Production Animals
6.3.1 Cattle
6.3.2 Swine
6.3.3 Poultry
6.3.4 Sheep & Goats
7 Global Veterinary Vaccine Market, By Disease
7.1 Introduction
7.2 Canine Distemper
7.3 Rabies
7.4 Avian Influenza
7.5 Newcastle Disease
7.6 Brucellosis
7.7 Bovine Viral Diarrhea (BVD)
7.8 Other Diseases
8 Global Veterinary Vaccine Market, By Technology
8.1 Introduction
8.2 Conventional Vaccines
8.3 Advanced Vaccines
9 Global Veterinary Vaccine Market, By End User
9.1 Introduction
9.2 Veterinary Hospitals & Clinics
9.3 Livestock Farms
9.4 Homecare Settings
9.5 Research Institutes
9.6 Other End Users
10 Global Veterinary Vaccine Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Zoetis Inc.
12.2 Boehringer Ingelheim GmbH
12.3 Merck & Co., Inc.
12.4 Ceva Santé Animale
12.5 Elanco Animal Health
12.6 Virbac S.A.
12.7 HIPRA
12.8 Phibro Animal Health Corporation
12.9 Vaxxinova International B.V.
12.10 Biogénesis Bagó
12.11 Hester Biosciences Limited
12.12 Indian Immunologicals Ltd.
12.13 Neogen Corporation
12.14 Tianjin Ringpu Bio Technology Co., Ltd.
12.15 China Animal Husbandry Group
12.16 Jinyu Bio technology Co., Ltd.
12.17 Ourofino Saúde Animal
12.18 Vetoquinol
List of Tables
1 Global Veterinary Vaccine Market Outlook, By Region (2024-2032) ($MN)
2 Global Veterinary Vaccine Market Outlook, By Type (2024-2032) ($MN)
3 Global Veterinary Vaccine Market Outlook, By Inactivated (Killed) Vaccines (2024-2032) ($MN)
4 Global Veterinary Vaccine Market Outlook, By Live Attenuated Vaccines (2024-2032) ($MN)
5 Global Veterinary Vaccine Market Outlook, By Toxoid Vaccines (2024-2032) ($MN)
6 Global Veterinary Vaccine Market Outlook, By Recombinant Vaccines (2024-2032) ($MN)
7 Global Veterinary Vaccine Market Outlook, By DNA Vaccines (2024-2032) ($MN)
8 Global Veterinary Vaccine Market Outlook, By Subunit Vaccines (2024-2032) ($MN)
9 Global Veterinary Vaccine Market Outlook, By Other Types (2024-2032) ($MN)
10 Global Veterinary Vaccine Market Outlook, By Animal (2024-2032) ($MN)
11 Global Veterinary Vaccine Market Outlook, By Companion Animals (2024-2032) ($MN)
12 Global Veterinary Vaccine Market Outlook, By Dogs (2024-2032) ($MN)
13 Global Veterinary Vaccine Market Outlook, By Cats (2024-2032) ($MN)
14 Global Veterinary Vaccine Market Outlook, By Production Animals (2024-2032) ($MN)
15 Global Veterinary Vaccine Market Outlook, By Cattle (2024-2032) ($MN)
16 Global Veterinary Vaccine Market Outlook, By Swine (2024-2032) ($MN)
17 Global Veterinary Vaccine Market Outlook, By Poultry (2024-2032) ($MN)
18 Global Veterinary Vaccine Market Outlook, By Sheep & Goats (2024-2032) ($MN)
19 Global Veterinary Vaccine Market Outlook, By Disease (2024-2032) ($MN)
20 Global Veterinary Vaccine Market Outlook, By Canine Distemper (2024-2032) ($MN)
21 Global Veterinary Vaccine Market Outlook, By Rabies (2024-2032) ($MN)
22 Global Veterinary Vaccine Market Outlook, By Avian Influenza (2024-2032) ($MN)
23 Global Veterinary Vaccine Market Outlook, By Newcastle Disease (2024-2032) ($MN)
24 Global Veterinary Vaccine Market Outlook, By Brucellosis (2024-2032) ($MN)
25 Global Veterinary Vaccine Market Outlook, By Bovine Viral Diarrhea (BVD) (2024-2032) ($MN)
26 Global Veterinary Vaccine Market Outlook, By Other Diseases (2024-2032) ($MN)
27 Global Veterinary Vaccine Market Outlook, By Technology (2024-2032) ($MN)
28 Global Veterinary Vaccine Market Outlook, By Conventional Vaccines (2024-2032) ($MN)
29 Global Veterinary Vaccine Market Outlook, By Advanced Vaccines (2024-2032) ($MN)
30 Global Veterinary Vaccine Market Outlook, By End User (2024-2032) ($MN)
31 Global Veterinary Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2024-2032) ($MN)
32 Global Veterinary Vaccine Market Outlook, By Livestock Farms (2024-2032) ($MN)
33 Global Veterinary Vaccine Market Outlook, By Homecare Settings (2024-2032) ($MN)
34 Global Veterinary Vaccine Market Outlook, By Research Institutes (2024-2032) ($MN)
35 Global Veterinary Vaccine Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
